Get started
Tempus AI, Inc.Tempus AI, Inc.Tempus AI, Inc.

Tempus AI, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

TEM trade ideas

TEM - Nov 24 Extended Mispriced AssetsStrategy - Extended Mispriced Assets 🌊 Idea TEM, a precision medical AI company recently listed on June 14, 2024, and featured on The Wall Street Journal, has demonstrated consistent growth over the past three quarters with improving EPS. Despite these strong fundamentals and a clear thematic focus on AI, TEM has been downtrending along with the broader market following the Trump rally. On November 21, it experienced a sharp bearish move, which appears to be tied to the broader market’s negative reaction to Nvidia's strong earnings. Given its robust business fundamentals and alignment with the AI growth narrative, I believe TEM is currently mispriced, presenting an opportunity to arbitrage this value as it normalises. Technical positioning - Confluence in RUT & SPX bull direction - Recent price consolidation below H1 100SMA - Trade is aligned to existing trend - Risk reward is 2.9R at the 12 Nov
NASDAQ:TEMLong
by Ronin_trader
Tempus AI (TEM) Investment Analysis Company Overview: Tempus AI NASDAQ:TEM specializes in AI-driven healthcare solutions, focusing on improving patient outcomes and accelerating medical research. By leveraging extensive datasets and advanced analytics, Tempus provides innovative precision medicine solutions, solidifying its position in the growing AI healthcare sector. Key Growth Drivers: Strategic Acquisition of Ambry Genetics: Tempus AI's acquisition of Ambry Genetics significantly enhances its capabilities in genetic testing. This deal, completed at favorable multiples of 1.9x revenue and 15x EBITDA, demonstrates strategic financial discipline. The integration of Ambry Genetics is expected to boost Tempus's market presence, expanding its offerings in diagnostics and genetic analysis, and driving revenue growth. Multi-Year Partnership with BioNTech: A new multi-year partnership with BioNTech is a major validation of Tempus AI's expertise in precision medicine. This collaboration will focus on leveraging Tempus's vast datasets and computational biology tools to enhance BioNTech's research and development in personalized treatments. The partnership could lead to significant advancements in oncology and other therapeutic areas, potentially resulting in considerable revenue gains from breakthrough discoveries and innovative treatment options. Competitive Edge in AI-Enabled Precision Medicine: Tempus AI's proprietary operating system and robust data library provide a competitive edge in the precision medicine market. The company's AI-driven platform allows for rapid analysis of complex datasets, aiding in the identification of personalized treatment options for patients. This competitive advantage positions Tempus to capture a larger market share as demand for AI-enabled healthcare solutions continues to grow. Technical Analysis and Investment Outlook: Current Price Level: We are bullish on Tempus AI (TEM) above the $43.00-$44.00 range. This level reflects investor optimism, particularly following recent strategic initiatives like the Ambry Genetics acquisition and the BioNTech partnership. Upside Potential: Our upside target for TEM is $85.00-$90.00, driven by expected revenue growth from new collaborations and enhanced genetic testing capabilities. Catalysts to Watch: Updates on the integration progress of Ambry Genetics, along with developments from the BioNTech partnership, are key catalysts to monitor. These could significantly impact Tempus's revenue trajectory and investor sentiment. 🔍 Tempus AI—Revolutionizing Healthcare with Precision Medicine! #PrecisionMedicine #HealthcareAI #GeneticTesting #BioNTechPartnership
NASDAQ:TEMLong
by Richtv_official